Nine Masts Capital’s Edwards Lifesciences EW Stock Holding History

Nine Masts Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-400,000	Closed	-$5.06M	–	89
2025 Q2	$5.06M	Buy	+400,000	New	+$29.8M	1.85%	14

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Nine Masts Capital's EW Position: Q3 2025 in Review

Nine Masts Capital sold out of Edwards Lifesciences (EW) in Q3 2025, closing a stake of 400,000 shares — an estimated $5.06M sold.

Nine Masts Capital first reported a position in EW in Q2 2025 and held it in 1 quarter. The position peaked at $5.06M in Q2 2025. 1,254 funds tracked by Wall St. Rank hold EW as of Q3 2025.

Nine Masts Capital reported no remaining Edwards Lifesciences position as of Q3 2025 after selling out during the quarter.
Nine Masts Capital sold 400,000 Edwards Lifesciences shares in Q3 2025, an estimated $5.06M.
Nine Masts Capital first reported a position in Edwards Lifesciences in Q2 2025 and held it in 1 quarter.
Nine Masts Capital's Edwards Lifesciences position peaked at $5.06M in Q2 2025.
1,254 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on Nine Masts Capital's 13F filing for Q3 2025, filed 13 Nov 2025.